Novo Nordisk today announced that the US Food and Drug Administration has approved the New Drug Application for Saxenda (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 analogue for the treatment of obesity. Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI =>30 kg/m2) or who are overweight (BMI =>27 kg/m2) with at least one weight-related comorbidity such as type 2 diabetes and cardiovascular disease.

For more details, go to: http://www.novonordisk.com/press/sea/novo-nordisk-news.asp?sShowNewsItemGUID=3e18b484-61ca-4ab8-93d0-da9a9ff4e333&sShowLanguageCode=en-GB